Analysts predict that Agile Therapeutics Inc (NASDAQ:AGRX) will report earnings of ($0.08) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Agile Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at ($0.07). Agile Therapeutics reported earnings per share of ($0.11) in the same quarter last year, which would suggest a positive year over year growth rate of 27.3%. The company is scheduled to issue its next earnings report on Thursday, November 7th.
According to Zacks, analysts expect that Agile Therapeutics will report full year earnings of ($0.37) per share for the current year, with EPS estimates ranging from ($0.39) to ($0.34). For the next fiscal year, analysts expect that the business will report earnings of ($0.35) per share, with EPS estimates ranging from ($0.77) to $0.11. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Agile Therapeutics.
Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03.
A number of brokerages have recently issued reports on AGRX. ValuEngine cut shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research cut shares of Agile Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $3.45.
Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in shares of Agile Therapeutics by 2,219.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock valued at $108,000 after buying an additional 73,238 shares in the last quarter. BlackRock Inc. raised its stake in shares of Agile Therapeutics by 27.2% in the 2nd quarter. BlackRock Inc. now owns 169,226 shares of the specialty pharmaceutical company’s stock valued at $247,000 after buying an additional 36,212 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Agile Therapeutics by 33.3% in the 1st quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock valued at $630,000 after buying an additional 104,222 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Agile Therapeutics by 129.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock valued at $2,530,000 after buying an additional 978,672 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Agile Therapeutics by 5.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,254,180 shares of the specialty pharmaceutical company’s stock valued at $3,291,000 after buying an additional 120,403 shares in the last quarter. Institutional investors own 43.73% of the company’s stock.
Agile Therapeutics stock traded down $0.01 during mid-day trading on Friday, reaching $1.13. The company had a trading volume of 11,263 shares, compared to its average volume of 1,233,939. Agile Therapeutics has a 52 week low of $0.51 and a 52 week high of $1.70. The company has a 50 day moving average of $1.18 and a 200-day moving average of $1.31. The firm has a market cap of $51.50 million, a price-to-earnings ratio of -1.93 and a beta of 0.38.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.
Further Reading: What is a stock buyback?
Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.